

(19)



(11)

EP 3 013 946 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

(15) Correction information:

**Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73**

(51) Int Cl.:

C12N 7/00 (2006.01) C07K 14/47 (2006.01)

(48) Corrigendum issued on:

10.04.2019 Bulletin 2019/15

(86) International application number:

PCT/EP2014/063676

(45) Date of publication and mention of the grant of the patent:

06.02.2019 Bulletin 2019/06

(87) International publication number:

WO 2014/207190 (31.12.2014 Gazette 2014/53)

(21) Application number: **14733199.5**

(22) Date of filing: **27.06.2014**

(54) **METHODS FOR EXPRESSING A POLYNUCLEOTIDE OF INTEREST IN THE RETINA OF A SUBJECT**

VERFAHREN ZUR EXPRESSION VON EINES POLYNUCLEOTIDS VON INTERESSE IN DER NETZHAUT EINER PERSON

PROCÉDÉS POUR L'EXPRESSION D'UN POLYNUCLÉOTIDE D'INTÉRÊT DANS LA RÉTINE D'UN SUJET

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

- **RENDON FUENTES, Alvaro**

F-75012 Paris (FR)

- **SAHEL, José Alain**

F-75012 Paris (FR)

- **VACCA, Ophélie**

F-75012 Paris (FR)

(30) Priority: **28.06.2013 EP 13305914**

(43) Date of publication of application:

04.05.2016 Bulletin 2016/18

(74) Representative: **Inserm Transfert**

7, rue Watt

75013 Paris (FR)

(73) Proprietors:

- **INSERM (Institut National de la Santé et de la Recherche Médicale)**
75013 Paris (FR)

- **Sorbonne Université**
75006 Paris (FR)

- **Centre National de la Recherche Scientifique (C.N.R.S.)**
75016 Paris (FR)

(56) References cited:

WO-A1-2010/149765 WO-A2-2010/000851

WO-A2-2010/011404 WO-A2-2012/145601

- **OPHÉLIE VACCA ET AL: "AAV-mediated gene delivery in Dp71-null mouse model with compromised barriers", GLIA, vol. 62, no. 3, 31 March 2014 (2014-03-31), pages 468-476, XP055141047, ISSN: 0894-1491, DOI: 10.1002/glia.22617**

(72) Inventors:

- **DALKARA, Deniz**
F-75012 Paris (FR)

EP 3 013 946 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- FORT P ET AL: "DYSTROPHIN PROTEIN DP71 AND RETINA: A NEW PHENOTYPE", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, XX, XX, vol. 2002, 5 May 2002 (2002-05-05), page 661, XP009085268,
- BRINGMANN A ET AL: "Muller cells in the healthy and diseased retina", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 25, no. 4, 1 July 2006 (2006-07-01), pages 397-424, XP028074816, ISSN: 1350-9462, DOI: 10.1016/J.PRETEYERES.2006.05.003 [retrieved on 2006-07-01]
- BERMUDEZ DE LEON M ET AL: "beta-naphthoflavone represses dystrophin Dp71 expression in Hepa-1 cells", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1759, no. 3-4, 1 March 2006 (2006-03-01), pages 152-158, XP027896498, ISSN: 0167-4781 [retrieved on 2006-03-01]
- Mario Bermúdez De León ET AL: "Dystrophin Dp71 Expression Is Down-regulated during Myogenesis : ROLE OF Sp1 AND Sp3 ON THE Dp71 PROMOTER ACTIVITY", Journal of Biological Chemistry, vol. 280, no. 7, 18 February 2005 (2005-02-18), pages 5290-5299, XP055444822, ISSN: 0021-9258, DOI: 10.1074/jbc.M411571200